Evidence map›Paper›PMID 35595169›Full record

ArticleJournal of molecular biology2022

Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.

Victoria R Mingione, Zachariah H Foda, YiTing Paung, Hannah Philipose, Aziz M Rangwala, Yibing Shan, Markus A Seeliger

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Resistance to Allosteric Inhibitors.Journal of molecular biology · 2025
    Review
  4. Review
  5. Allosteric regulation and inhibition of protein kinases.Biochemical Society transactions · 2023
    Review
  6. AlphaFold, Artificial Intelligence (AI), and Allostery.The journal of physical chemistry. B · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Victoria R MingioneStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA.
Zachariah H FodaStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA.
YiTing PaungStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA.
Hannah PhiliposeStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA.
Aziz M RangwalaStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA.
Yibing ShanAntidote Health Foundation for Cure of Cancer, Cambridge, MA 02139, USA. Electronic address: yibing.shan@antidotehealthfoundation.org.
Markus A SeeligerStony Brook University Renaissance School of Medicine, Department of Pharmacological Sciences, Stony Brook, NY 11794, USA. Electronic address: markus.seeliger@stonybrook.edu.
Stony Brook School · USStony Brook University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6M
Dynamics of Ligand Binding and Protein Kinase Regulation_RenewalR35GM119437 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Markus A Seeliger · 2016 to 2026
$6.5M
Scholars in BioMedical Sciences (SBMS) Training ProgramT32GM127253 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI TSIRKA, STYLIANI-ANNA (STELLA) E · 2018 to 2022
$689k
Elucidating the Role of Binding Kinetics in the Development of Abl Kinase Drug ResistanceF30CA260771 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI RANGWALA, AZIZ MOHAMMEDI · 2021 to 2024
$184k
Robotic assay platformS10OD028478 · OD · STATE UNIVERSITY NEW YORK STONY BROOK · PI SEELIGER, MARKUS A · 2020 to 2020
$173k
NCI NIH HHS F30 CA260771NIGMS NIH HHS R35 GM119437NIGMS NIH HHS T32 GM008444NIGMS NIH HHS T32 GM127253NIH HHS S10 OD028478
6 · The paper itself

Abstract

Allostery plays a primary role in regulating protein activity, making it an important mechanism in human disease and drug discovery. Identifying allosteric regulatory sites to explore their biological significance and therapeutic potential is invaluable to drug discovery; however, identification remains a challenge. Allosteric sites are often "cryptic" without clear geometric or chemical features. Since allosteric regulatory sites are often less conserved in protein kinases than the orthosteric ATP binding site, allosteric ligands are commonly more specific than ATP competitive inhibitors. We present a generalizable computational protocol to predict allosteric ligand binding sites based on unbiased ligand binding simulation trajectories. We demonstrate the feasibility of this protocol by revisiting our previously published ligand binding simulations using the first identified viral proto-oncogene, Src kinase, as a model system. The binding paths for kinase inhibitor PP1 uncovered three metastable intermediate states before binding the high-affinity ATP-binding pocket, revealing two previously known allosteric sites and one novel site. Herein, we validate the novel site using a combination of virtual screening and experimental assays to identify a V-type allosteric small-molecule inhibitor that targets this novel site with specificity for Src over closely related kinases. This study provides a proof-of-concept for employing unbiased ligand binding simulations to identify cryptic allosteric binding sites and is widely applicable to other protein-ligand systems.

Indexed as

Adenosine TriphosphateComputer SimulationProtein Kinase Inhibitorssrc-Family KinasesAllosteric RegulationAllosteric SiteBinding SitesHumansLigandsProtein BindingAdenosine TriphosphateLigandsProtein Kinase Inhibitorssrc-Family Kinasescancerdockingdrug binding processinhibitorNMR

Identifiers

PMID35595169
PMCPMC9713948
OpenAlexW4280587287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.